Growth hormone and kidney function are closely connected through the regulation of renal blood flow, filtration and electrolyte balance. Although growth hormone (GH) is primarily associated with growth and metabolism, the kidneys are important targets of GH and insulin-like growth factor 1 (IGF-1) signalling.
Research demonstrates that these hormones influence glomerular filtration rate, sodium retention and renal tissue activity. The kidneys also participate in the clearance and metabolism of circulating GH and IGF-1.
The relationship becomes particularly important in conditions involving GH deficiency, chronic GH excess and chronic kidney disease.
How Does Growth Hormone Affect the Kidneys?
The kidneys contain receptors for both GH and IGF-1.
These receptors are expressed in several renal structures, including glomerular and tubular cells.
GH can influence kidney physiology directly through its receptor or indirectly through IGF-1 produced in the liver and within renal tissues.
One important distinction is that the effects of GH and IGF-1 are not identical. Some renal responses are mediated predominantly by IGF-1, while others involve direct GH receptor signalling.
6 Research Insights Into Growth Hormone and Kidney Function
1. GH and IGF-1 Influence Glomerular Filtration
The glomeruli filter blood to produce the initial fluid that enters the renal tubules.
Glomerular filtration rate (GFR) is an important measurement of this process.
Human studies have demonstrated that GH activity can influence both GFR and renal plasma flow.
However, these changes are often delayed following increased GH exposure.
IGF-1 appears to mediate much of this response by influencing renal blood vessel function and nitric oxide signalling.
Experimental studies have shown that IGF-1 can increase renal blood flow and filtration more rapidly than GH.
This distinction supports the importance of downstream hormone activity in renal physiology.
2. Growth Hormone Can Increase Sodium and Water Retention
The kidneys regulate extracellular fluid volume by controlling sodium and water excretion.
GH and IGF-1 can influence sodium transport within renal tubular cells.
Research has identified interactions involving epithelial sodium channels, commonly abbreviated as ENaC, in the distal nephron.
Increased sodium reabsorption can contribute to extracellular fluid expansion.
This helps explain why excessive GH activity is sometimes associated with fluid retention and swelling.
The finding also illustrates that changes in body weight or lean body mass may partly reflect fluid balance rather than tissue growth.
3. The GH–IGF-1 Axis Influences Mineral Handling
GH and IGF-1 participate in renal phosphate and calcium regulation.
Experimental evidence indicates that IGF-1 can increase phosphate reabsorption through sodium-phosphate transport mechanisms in the proximal tubule.
The GH–IGF-1 axis also influences the renal production of active vitamin D, known as calcitriol.
These pathways contribute to the regulation of mineral metabolism.
They are particularly relevant when studying interactions between endocrine function, renal physiology and skeletal development.
Our growth hormone and bone metabolism article examines the skeletal effects of GH and IGF-1 in greater detail.
4. Chronic GH Excess Can Produce Renal Hyperfiltration
Acromegaly is characterised by prolonged excessive GH activity, usually accompanied by elevated IGF-1.
Clinical studies have associated acromegaly with increased kidney size and elevated glomerular filtration.
Although a higher filtration rate may initially appear beneficial, persistent hyperfiltration can place additional stress on renal structures.
Experimental studies have also linked excessive GH signalling with podocyte abnormalities and glomerular injury.
Podocytes are specialised cells that contribute to the kidney’s filtration barrier.
However, not every person with acromegaly develops progressive kidney disease.
The relationship depends on disease duration, hormonal exposure and associated conditions such as hypertension and diabetes.
5. Chronic Kidney Disease Alters GH–IGF-1 Regulation
The relationship between the kidneys and the GH axis operates in both directions.
Chronic kidney disease (CKD) can alter GH clearance, receptor responsiveness and IGF-binding protein concentrations.
Children with advanced CKD may experience impaired growth despite circulating GH concentrations that are normal or elevated.
This phenomenon reflects, in part, reduced tissue responsiveness to GH.
Changes in IGF-binding proteins can also influence the availability of biologically active IGF-1.
Consequently, circulating hormone concentrations may not accurately represent endocrine activity within renal or skeletal tissues.
For further context, our growth hormone and IGF-1 research guide explains the distinction between hormone secretion and downstream signalling.
6. The Kidneys Participate in GH and IGF-1 Clearance
The kidneys are not simply passive targets of endocrine signals.
They also contribute to the metabolism and clearance of circulating hormones.
GH undergoes glomerular filtration, tubular uptake and intracellular degradation.
IGF-1 handling is more complex because most circulating IGF-1 is associated with binding proteins.
Renal impairment can therefore alter hormone concentrations through changes in clearance, binding protein metabolism and feedback regulation.
This is an important consideration when comparing GH–IGF-1 measurements between individuals with normal and impaired kidney function.
Growth Hormone Deficiency, Excess and Chronic Kidney Disease
The renal effects of GH depend on the underlying physiological or clinical condition.
| Condition | Typical GH-axis characteristic | Relevant renal finding |
|---|---|---|
| Normal GH physiology | Regulated GH and IGF-1 signalling | Supports normal filtration and tubular function |
| GH deficiency | Reduced GH activity | Lower renal plasma flow or GFR in some studies |
| Acromegaly | Chronic GH and IGF-1 excess | Renal hypertrophy and hyperfiltration |
| Chronic kidney disease | Altered clearance and GH responsiveness | Changes in GH–IGF-1 regulation |
| Severe GH resistance | Impaired receptor-mediated signalling | Altered IGF-1-dependent renal responses |
These are research patterns rather than standalone diagnostic criteria.
Why Higher GFR Does Not Always Mean Better Kidney Function
A particularly important distinction in renal research is the difference between increased filtration and improved kidney health.
GFR measures the volume of fluid filtered by the glomeruli over time.
An increase may reflect a physiological response to changes in renal blood flow.
However, sustained hyperfiltration can also occur in disease states and may contribute to long-term renal stress.
Similarly, a decline in an initially elevated GFR after successful treatment of acromegaly may reflect normalisation of hyperfiltration rather than deterioration in kidney function.
Researchers should therefore interpret GFR alongside other measurements, including albuminuria, blood pressure and the underlying clinical context.
What Should GH–Kidney Research Measure?
Studies examining growth hormone and kidney function can use several complementary measurements.
Glomerular filtration rate: Provides information about filtration activity.
Renal plasma flow: Helps characterise blood delivery to the kidneys.
Urinary albumin: Can provide evidence of abnormalities affecting the filtration barrier.
Serum GH and IGF-1: Help characterise endocrine activity, although both require appropriate interpretation.
Sodium and phosphate handling: Provide information about tubular transport processes.
Renal imaging: Can help assess kidney size and structural changes in selected research settings.
The choice of measurement should depend on whether the study concerns renal haemodynamics, tubular physiology or chronic structural changes.
Understanding the Wider Endocrine Relationship
GH–IGF-1 signalling interacts with several physiological systems, including cardiovascular regulation, glucose metabolism and skeletal development.
These connections help explain why changes in renal physiology can accompany broader endocrine abnormalities.
Our growth hormone and cardiovascular health article examines related effects on blood vessels, blood pressure and cardiac function.
For laboratories exploring endocrine signalling and peptide-related molecular research, Peptide Lab Direct UK is our featured UK research peptide supplier, offering a specialist platform for research compounds relevant to cellular and molecular studies.
Frequently Asked Questions
Does growth hormone affect kidney function?
Yes. GH and IGF-1 influence renal blood flow, filtration and several tubular transport processes.
Can growth hormone increase glomerular filtration rate?
Yes. Studies demonstrate that GH-related increases in IGF-1 can influence renal plasma flow and GFR.
Why does growth hormone cause fluid retention?
GH and IGF-1 can increase renal sodium reabsorption, contributing to extracellular fluid expansion.
Can excessive growth hormone damage the kidneys?
Chronic GH excess is associated with renal hypertrophy and hyperfiltration, while experimental studies have identified mechanisms of glomerular injury.
Does chronic kidney disease affect growth hormone levels?
Yes. CKD can alter GH clearance, receptor responsiveness and IGF-1-related regulation.
Are the kidneys involved in growth hormone clearance?
Yes. Renal filtration, tubular uptake and intracellular degradation contribute to GH metabolism.
Scientific References
- Hafner A et al. (2021). Renal effects of growth hormone in health and in kidney disease. Pediatric Nephrology.
https://pmc.ncbi.nlm.nih.gov/articles/PMC8260426/ - Kamenický P et al. (2014). Growth hormone, insulin-like growth factor-1, and the kidney: pathophysiological and clinical implications. Endocrine Reviews.
https://pubmed.ncbi.nlm.nih.gov/24423979/ - Growth Hormone and IGF1 Actions in Kidney Development and Function. Cells, 2021.
https://pmc.ncbi.nlm.nih.gov/articles/PMC8699155/ - The growth hormone–insulin-like growth factor-I axis in chronic kidney disease. Scientific review.
https://pmc.ncbi.nlm.nih.gov/articles/PMC2706146/
Research-only notice: This article is provided for scientific education and laboratory research. It does not constitute medical advice or instructions for administering research compounds.
